Q32 Bio Newsroom

Q32 Bio Is Maintained at Outperform by BMO Capital

Dow JonesDec 12 11:27 ET

BMO Capital Maintains Q32 Bio(QTTB.US) With Buy Rating, Cuts Target Price to $22

Moomoo NewsDec 12 10:32 ET

Q32 Bio Analyst Ratings

BenzingaDec 12 10:14 ET

Guggenheim Downgrades Q32 Bio(QTTB.US) to Hold Rating

Moomoo NewsDec 11 11:31 ET

Q32 Bio Is Maintained at Overweight by Piper Sandler

Dow JonesDec 11 08:20 ET

Q32 Bio Price Target Cut to $16.00/Share From $95.00 by Wells Fargo

Dow JonesDec 11 08:07 ET

Q32 Bio (QTTB) Receives a Buy From Oppenheimer

TipRanksDec 11 07:52 ET

Leerink Partners Downgrades Q32 Bio to Market Perform, Lowers Price Target to $9

BenzingaDec 11 06:58 ET

Piper Sandler Reaffirms Their Buy Rating on Q32 Bio (QTTB)

TipRanksDec 11 06:47 ET

Raymond James Downgrades Q32 Bio to Outperform, Lowers Price Target to $22

BenzingaDec 11 06:17 ET

Q32 Bio Analyst Ratings

BenzingaDec 11 06:16 ET

Q32 Bio Downgraded to Equal Weight From Overweight at Wells Fargo

TipRanksDec 10 21:17 ET

Q32 Bio Initiated at Outperform by BMO Capital

Dow JonesDec 6 06:29 ET

Q32 Bio Analyst Ratings

BenzingaDec 6 06:19 ET

BMO Capital Initiates Q32 Bio(QTTB.US) With Buy Rating, Announces Target Price $64

Moomoo NewsDec 5 17:31 ET

Positive Outlook for Q32 Bio: Buy Rating Backed by Promising Clinical Timelines and Increased Price Target

TipRanksNov 11 01:31 ET

Wells Fargo Maintains Q32 Bio(QTTB.US) With Buy Rating, Maintains Target Price $95

Moomoo NewsNov 5 05:40 ET

Raymond James Initiates Q32 Bio at Strong Buy With $90 Price Target

MT NewswiresOct 24 08:18 ET

Oppenheimer Maintains Q32 Bio(QTTB.US) With Buy Rating, Raises Target Price to $80

Moomoo NewsOct 16 08:31 ET

Q32 Bio Initiated at Overweight by Wells Fargo

Dow JonesSep 11 09:04 ET